Faruqi and Faruqui, LLP Logo
Share this page

Neurotrope, Inc. (NTRP)

NASDAQ:NTRP

Summary

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Neurotrope, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Neurotrope, Inc. (“Neurotrope” or the “Company”) (NASDAQ:NTRP) of the July 17, 2017 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you invested in Neurotrope stock or options between January 7, 2016 and April 28, 2017 and would like to discuss your legal rights, please fill out the form below.  You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com. 

The lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of all those who purchased Neurotrope securities between January 7, 2016 and April 28, 2017 (the “Class Period”).  The case, Hinshaw et al v. Neurotrope, Inc. et al., No. 17-cv-03718 was filed on May 17, 2017, and has been assigned to Judge Lorna G. Schofield.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by misrepresenting the ability of its lead candidate drug for the treatment of severe Alzheimer's disease, Bryostatin-1, to provide effective results. 

Specifically, on May 1, 2017, Neurotrope announced “positive top-line results” of the focal Phase 2b trials of Bryostatin-1.  Among other statements, the Company mentioned that the results showed “improvement in patients with moderate to severe Alzheimer's disease.” However, upon further analysis, the trial data pertaining to the 20-microgram dose failed to demonstrate statistical significance with regard to the primary endpoint of efficacy.  As well, the Company failed to provide results on the efficacy of the 40-microgram dose.

After the announcement, Neurotrope’s share price fell from $18.81 per share on April 28, 2017 to a closing price of $6.97 on May 1, 2017—a $11.84 or a 62.9% drop.

Request Information

Please tell us about yourself by completing the form and we will provide you with additional
information on how to join the Class Action at no cost to you.

  • Case:
    Neurotrope, Inc. (NTRP)
  •    

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330

Email:

Case Details

Date:

  • 05/19/2017

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.